However, TLR7 and TLR8 selective agonists or antagonists, inducing antiviral IFN response and/or controlling inflammation, deserve consideration and have entered phase II clinical trials as interesting therapeutic options to control the different manifestations of COVID-19 (ClinicalTrials.gov NCT04448756). The gene discussed is TLR8; the disease is COVID-19.